zolbetuximab
astellas,leap therapeutics
[]
here's a strange thing though: zolbetuximab efficacy seems to have been entirely driven by gastric cancer. no activity in gej (caveat: small patient numbers). any comments from gi docs? $alpmy $lptx #gi23 
Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today.